Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Conditions: Malignant Digestive System Neoplasm
Interventions: Procedure: Biospecimen Collection; Drug: Capecitabine; Drug: Diltiazem Hydrochloride; Procedure: Electrocardiogram; Drug: Fluorouracil; Device: Holter Monitoring; Drug: Isosorbide Mononitrate; Other: Medical Device Usage and Evaluation; Drug: Placebo Administration; Other: Questionnaire Administration
Sponsors: Mayo Clinic
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 10, 2026Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Comments